Moreover, we further examined the efficacy of FDA-approved SPHK1 inhibitor (i.e., FTY720) in reducing bladder cancer metastasis using in vivo orthotopically metastatic xenograft model. This evidence concerns the gene SPHK1 and urinary bladder carcinoma.